TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01414907

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health promotion activities
Description: Counselled activities on tobacco smoking secession, diet correlation and physical activities
Study: NCT01819077

Intervention type: PROCEDURE
Intervention: TMMR
Description: Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
Study: NCT03103633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mean artery pressure
Description: mean artery pressure declined with less than 20% of baseline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bispectral index
Description: BIS 45-60 before and after CPB; and BIS 40-45 during CPB

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain oxygen saturation
Description: Brain oxygen saturation declined with less than 20% of baseline

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Controlled
Description: receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
Study: NCT00735592

Intervention type: OTHER
Intervention: Observational
Description: Retrospective data obtained from electronic files
Study: NCT03460665

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriography
Description: knee arteriography
Study: NCT02826707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPPAC intervention
Description: A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
Study: NCT03460665

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arteriography
Description: knee arteriography
Study: NCT01725620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBEC0101 (Etanercept 25mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBEC0101 (Etanercept 25mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel (Etanercept 25mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel (Etanercept 25mg)
Study: NCT04154020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexor tenotomy
Description: Tenotomy(cutting) of flexor tendons is performed with needle
Study: NCT01304901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast 4 mg granule
Description: Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast placebo granüle
Description: Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
Study: NCT02282020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLAPARIB
Description: 300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single agent chemotherapy
Description: Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
Study: NCT01816633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoloGel
Description: AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
Study: NCT02257788

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140
Description: Humanized monoclonal antibody to CCR5

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140
Description: Humanized monoclonal antibody to CCR5

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140
Description: Humanized monoclonal antibody to CCR5

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140
Description: Humanized monoclonal antibody to CCR5
Study: NCT02064894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral morphine and oral ibuprofen
Description: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
Study: NCT04460391

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive rehabilitation
Description: Early standing training and routine rehabilitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation
Description: Early standing training and routine rehabilitation
Study: NCT02064894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral morphine
Description: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ibuprofen
Description: oral ibuprofen combine to a placebo is the active comparator
Study: NCT03542968

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: magnetic resonance imaging
Description: Acquisition 4D Flow magnetic resonance Imaging-8 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Acquisition 4D Flow magnetic resonance Imaging-8 minutes
Study: NCT02329249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smokefree Partners: 21 Days to Freedom
Description: Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-List Control
Description: Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
Study: NCT02350725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide injection solution for subcutaneous administration (80 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide injection solution for subcutaneous administration (80 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Furosemide tablets (80 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Furosemide tablets (80 mg)
Study: NCT00551733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel poliglumex
Description: Given IV
Study: NCT00293254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir potassium
Description: Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
Study: NCT03395886

Intervention type: DRUG
Intervention: Remifentanil
Description: The noninvasive ventilation intolerated patients was sedated by remifentanil.

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
Study: NCT02711540

Intervention type: PROCEDURE
Intervention: Balloon Aortic Valvuloplasty
Description: Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
Study: NCT02450240

Intervention type: BEHAVIORAL
Intervention: standardized diagnostic assessment

Intervention type: BEHAVIORAL
Intervention: standardized diagnostic assessment
Study: NCT02510859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic nutritional consultation at home
Description: Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient.
Study: NCT03483883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab IV 10 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks
Study: NCT02184182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VLS ablation/portal ligation/hepatectomy
Description: Step1:~* exploratory laparoscopy to exclude extrahepatic disease~* right portal vein ligation if surgically feasible~* RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~* radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight \> 0.5~- laparoscopic/laparotomic right trisectionectomy
Study: NCT02452346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tosedostat
Description: 120 mg PO once daily continuously for each 28 day treatment cycle
Study: NCT04384666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
Description: LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neupro 4 mg / 24 Hr. Transdermal Patch
Description: Neupro 4 mg /24 Hr. Transdermal Patch
Study: NCT00475176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-adenosyl methionine for Chronic Liver Disease
Study: NCT02178631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: Online self-help

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAU
Description: Care as usual
Study: NCT03804879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nidufexor
Description: 50 mg (two 25 mg) LMB763 capsules for oral administration
Study: NCT00387413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Placebo
Description: Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Placebo
Description: Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Placebo
Description: Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
Study: NCT02436668

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Study: NCT05617053

Intervention type: DEVICE
Intervention: DAART

Intervention type: DEVICE
Intervention: ATP/Supera stenting
Study: NCT01897753

Intervention type: DRUG
Intervention: growth hormone
Description: 36 months
Study: NCT02291757

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NEM brand eggshell membrane
Description: NEM 500 mg, once daily, p.o.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 500 mg, once daily, p.o.
Study: NCT02637427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma transfusion
Description: Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
Study: NCT01838265

Intervention type: PROCEDURE
Intervention: Transrectal Ultrasound-Guided Biopsy
Description: Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).

Intervention type: PROCEDURE
Intervention: MRI Ultrasound Biopsy
Description: MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)

Intervention type: BEHAVIORAL
Intervention: Expanded Prostate Cancer index Composite Questionnaire
Description: Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy

Intervention type: BEHAVIORAL
Intervention: Expanded Prostate Cancer index Composite Questionnaire
Description: Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy

Intervention type: BEHAVIORAL
Intervention: Short-Form 12 of Health Related Quality of Life Questionnaire
Description: Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy

Intervention type: BEHAVIORAL
Intervention: Short-Form 12 of Health Related Quality of Life Questionnaire
Description: Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
Study: NCT03804879

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for oral administration
Study: NCT01838265

Intervention type: BEHAVIORAL
Intervention: Memorial Anxiety Scale for Prostate Cancer
Description: Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy

Intervention type: BEHAVIORAL
Intervention: Memorial Anxiety Scale for Prostate Cancer
Description: Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy

Intervention type: PROCEDURE
Intervention: Plasma/Serum Sample for biomarkers
Description: Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)

Intervention type: PROCEDURE
Intervention: Plasma/Serum Sample for biomarkers
Description: Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)

Intervention type: PROCEDURE
Intervention: Urine Sample for Biomarkers
Description: Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)

Intervention type: PROCEDURE
Intervention: Urine Sample for Biomarkers
Description: Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)

Intervention type: PROCEDURE
Intervention: Blood Tests for Blood Urea Nitrogen and Creatinine
Description: Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse

Intervention type: PROCEDURE
Intervention: Blood Tests for Blood Urea Nitrogen and Creatinine
Description: Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse

Intervention type: PROCEDURE
Intervention: Blood Test for Serum PSA
Description: Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.

Intervention type: PROCEDURE
Intervention: Blood Test for Serum PSA
Description: Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
Study: NCT02310854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Repair
Description: augmented suture of acute ACL rupture (\<3 weeks after injury)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction
Description: reconstruction hamstring autograft
Study: NCT03690492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Box 2.0
Description: Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
Study: NCT01567501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine Dihydrochloride tablets 5 mg
Description: 5 mg tablet once in a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine Dihydrochloride
Description: 5 mg tablet once in a day
Study: NCT01860157

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brainsway H1-Coil Deep TMS System (Sham treatment)
Description: In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brainsway H1-Coil Deep TMS System
Description: Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
Study: NCT03457506

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Digital PET/CT scan
Description: The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
Study: NCT03670329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URGO2875
Description: Dressing
Study: NCT01255007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR imaging
Description: Primovist enhanced MRI, Diffusion weighted MRI
Study: NCT03804879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SoC)
Description: Optimal tolerated doses of angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)
Study: NCT00479661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continuous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Continuous infusion
Study: NCT03858088

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation from deceased donors

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation from deceased donors
Study: NCT00788151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYD Dengue Vaccine Serotypes 1, 2, 3, and 4
Description: 0.5 mL, Subcutaneous (SC)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine
Description: 0.5 mL, SC
Study: NCT04640545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBL-007
Description: LBL-007 will be administered intravenously every two weeks (Q2W) at doses of Dose A, Dose B, Dose C,Dose D .
Study: NCT02450240

Intervention type: BEHAVIORAL
Intervention: standardized diagnostic assessment

Intervention type: BEHAVIORAL
Intervention: standardized diagnostic assessment

Intervention type: BEHAVIORAL
Intervention: self-report questionnaires

Intervention type: BEHAVIORAL
Intervention: self-report questionnaires
Study: NCT04640545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab Injection will be administered by intravenously (Q2W) by the fixed dose of 3 mg/kg .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib Tablets
Description: Axitinib Tablets 5mg and Axitinib Tablets 1mg(On-demand administration)
Study: NCT00375895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciclosporin
Description: ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
Study: NCT02318303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP 301-1 NS (QD)
Description: GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP 301-2 NS (BID)
Description: GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP 301 Placebo NS
Description: GSP 301 placebo NS administered as 2 sprays/nostril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine HCl-1 NS (QD)
Description: Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine HCl-2 NS (BID)
Description: Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate-1 NS (QD)
Description: Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate-2 NS (BID)
Description: Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril
Study: NCT02970448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LITT
Description: MRI-guided laser interstitial thermal therapy uses a gas cooled side-firing (directional) laser and a variety of procedure specific tools to thermally ablate target tissue in-situ.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: One treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks. All portals shall be treated during each treatment session. Doses are specified such that at least 95% of the planning target volume (PTV) shall receive 100% of the prescribed dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days
Study: NCT03306446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Start adalimumab in monotherapy
Description: Discontinuation of Adalimumab in patients who achieved deep remission